Micrographia Bio is pioneering advancements in drug discovery through the innovative application of spatial proteomics. This technology enables the rapid and precise identification of molecular interactions, which is crucial for understanding the mechanisms of action of potential therapeutics. By leveraging highly multiplexed microscopy combined with state-of-the-art machine vision, Micrographia Bio's platform offers a unique approach to visualize and analyze complex biological systems at a molecular level, thereby enhancing the drug discovery process.

The company's deeptech imaging platform is designed to operate autonomously, utilizing intelligent systems to streamline the analysis of proteomic data. This capability not only accelerates the discovery of new medicines but also provides researchers with unprecedented insights into the underlying biological processes of diseases. By integrating advanced microscopy techniques with machine learning, Micrographia Bio is positioned to transform the landscape of drug development, making it more efficient and effective in addressing various diseases.

United Kingdom

Micrographia Bio (MGB) has developed a new approach which uses spatial proteomics for stunningly sensitive and high-throughput assessment of the true molecular effects of drug candidates.

Micrographia Bio

Company Details